---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000137"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:31:23.949379+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Arvinas delays VERITAC-2 Phase 3 top-line data to Q1 2025

## Summary
- Enrollment for vepdegestrant monotherapy trial in 2L breast cancer completed in Q4 2024.
- Primary completion date reprojected from November 2024 to January 2025.
- Top-line data now expected in the first quarter of 2025 instead of late 2024.
- Company and Pfizer cite routine evaluation of blinded event rates for the adjustment.

## SEC filing metadata
- accession: 0001655759-24-000137
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/0001655759-24-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/arvn-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000137
- JSON: https://secwatch.observer/filing/0001655759-24-000137.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.